| Description | Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor. Taribavirin hydrochloride is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells and the development of hemolytic anemia [2]. |
| In vitro | Taribavirin hydrochloride (0-2 μM; 24 hours) obviously induces MCF-7 cell death. It recording half inhibitory effect (IC50) of 0.756 μM in MCF-7 cells [1]. |
| molecular weight | 279.68 |
| Molecular formula | C8H14ClN5O4 |
| CAS | 40372-00-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Abd-Rabou AA, et al. Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer. Pharm Res. 2018 Feb 27;35(4):76. 2. Deming P, et al. Taribavirin in the treatment of hepatitis C. Expert Opin Investig Drugs. 2011 Oct;20(10):1435-43. |